Concepedia

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial

Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Silvio E. Inzucchi, Renato D. Lópes, Darren K. McGuire, Julia B. Lewis, Matthew C. Riddle,

The Lancet Diabetes & Endocrinology · 2025 · 30 citations · 33 references

DOI

Concepts

References

33

A Proportional Hazards Model for the Subdistribution of a Competing Risk

Jason P. Fine · Journal of the American Statistical Association · 1999 · 13.6K citations

, , +15

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

, , +15

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

, , +17

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Paul E. Stevens, Sofia B. Ahmed, Juan Jesús Carrero et al. · Kidney International · 2024 · 7.4K citations · Full text

, , +17

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi et al. · New England Journal of Medicine · 2019 · 6.9K citations · Full text

, , +14